View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 20, 2021updated 12 Jul 2022 11:29am

ImmunityBio to begin Covid-19 vaccine candidate trial in South Africa

ImmunityBio is set to initiate a Phase I clinical trial of its novel subcutaneous Covid-19 vaccine candidate, hAd5 T-cell, in South Africa, where the 501Y.V2 strain of SARS-CoV-2 was found.

ImmunityBio is set to initiate a Phase I clinical trial of its novel subcutaneous Covid-19 vaccine candidate, hAd5 T-cell, in South Africa, where the 501Y.V2 strain of SARS-CoV-2 was found.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The latest development comes after the company secured the South Africa Health Products Regulatory Authority (SAHPRA) authorisation to begin the trial.

HAd5-COVID-19 targets both the mutation-prone outer spike protein (S) and the more stable inner nucleocapsid (N) protein. It can activate antibodies, memory B cells and T-cells against the virus.

The vaccine candidate administered subcutaneously and as a room temperature stable oral capsule formulation can potentially act as a universal T-cell boost to existing vaccines or address mutations where others could fail, such as the 501Y.V2 variant.

It is currently being analysed in a similar Phase I trial in the US, with no safety concerns noted so far.

ImmunityBio chairman and CEO Patrick Soon-Shiong said: “Unlike antibody-based vaccines, T-cell-based vaccines kill the infected cell, preventing virus replication and could provide long-term immune memory to recipients.

“Pursuing a vaccine that does not rely solely on targeting the S protein where the mutations are occurring is of critical importance as multiple variants of the SARS-CoV-2 virus have appeared globally, with concentrated outbreaks beginning in South Africa.

“After leveraging this concept in our novel Covid-19 oral vaccines, we saw complete protection to a viral challenge in our non-human primate data.”

ImmunityBio noted that recruitment for this trial of subcutaneous doses of the vaccine will start next month in Cape Town, South Africa. It will be followed by trials using sublingual doses as well as room temperature stable oral capsules.

Last month, ImmunityBio reported that a challenge study showed its Covid-19 vaccine candidate provided complete protection of nasal and lung airways of non-human primates against the SARS-CoV-2 virus.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena